KDRH - Planning 1 for 6 r/s as part of share exchange agreement
"The Agreement further provides that the Registrant: (i) file a registration statement on Form S-1 for the purpose of registering the Post-Reverse Shares issuable to the BioPharma Shareholders, subject to certain limitations; (ii) file an Information Statement on Schedule 14C with the SEC providing for a reverse split of the Registrant's 22,710,192 presently issued and outstanding shares of common stock on a one-for-six (1:6) basis, among other corporate actions; and (iii) apply for and receive approval from FINRA regarding the corporate actions. "
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.